3BNC117

**3BNC117** is an investigational recombinant human IgG1 kappa broadly neutralizing monoclonal antibody for **HIV-1** treatment and prevention. It was originally isolated from an HIV-infected viremic controller and binds the **CD4 binding site on the HIV-1 envelope glycoprotein gp120**, thereby blocking viral attachment and entry into susceptible host cells. The program originated at **Rockefeller University** and has also been associated with development efforts by **Gilead Sciences** in the broader 3BNC117 franchise, particularly alongside longer-acting derivatives and combination antibody strategies. Clinical studies have shown antiviral activity including transient suppression of viremia and delayed viral rebound during analytical treatment interruption, although monotherapy can select for resistant virus, supporting use in combination approaches.

Other names

3BNC-117